Axsome Therapeutics, Inc. (NASDAQ: AXSM)

$235.17 ▲ +11.14 (+4.97%)

As of May 13, 2026 03:59 PM

Sector: Healthcare Industry: Biotechnology CIK: 0001579428

Market Cap 12.04 Bn

P/E -63.22

P/S 17.00

Div. Yield 0.00

ROIC (Qtr) 0.00

Total Debt (Qtr) 129.00 Mn

Revenue Growth (1y) (Qtr) 57.42

Add ratio to table...

About

Axsome Therapeutics, Inc. is a fully integrated biopharmaceutical company focused on developing innovative medicines for central nervous system conditions. The company identifies critical gaps in care and creates differentiated products with novel mechanisms of action that have the potential to transform patient outcomes. Its portfolio includes three FDA approved commercial products: AUVELITY for major depressive disorder, SUNOSI for excessive daytime sleepiness associated with obstructive sleep apnea or narcolepsy, and SYMBRAVO for the acute treatment...

Axsome Therapeutics, Inc. is a fully integrated biopharmaceutical company focused on developing innovative medicines for central nervous system conditions. The company identifies critical gaps in care and creates differentiated products with novel mechanisms of action that have the potential to transform patient outcomes. Its portfolio includes three FDA approved commercial products: AUVELITY for major depressive disorder, SUNOSI for excessive daytime sleepiness associated with obstructive sleep apnea or narcolepsy, and SYMBRAVO for the acute treatment of migraine with or without aura in adults. Beyond these marketed therapies, Axsome advances a deep pipeline of investigational candidates targeting serious neurological and psychiatric disorders.

Axsome generates revenue primarily from the sale of its three commercial products in the United States. In 2025 total revenues from AUVELITY, SUNOSI and SYMBRAVO reached $638.5 million reflecting a 66 percent increase compared with 2024. The company also earns royalties and milestone payments from licensing agreements but product sales constitute the core of its revenue stream.

The company operates through the following segments.

• Commercial Products: This segment includes AUVELITY which combines dextromethorphan and bupropion with metabolic inhibition technology to deliver NMDA receptor antagonism for major depressive disorder; SUNOSI which uses solriamfetol as a dopamine and norepinephrine reuptake inhibitor TAAR1 agonist and serotonin 1A agonist to treat excessive daytime sleepiness linked to obstructive sleep apnea or narcolepsy; and SYMBRAVO which employs MoSEIC technology to combine cyclooxygenase 2 inhibition with serotonin 1B/1D receptor agonism for the acute treatment of migraine with or without aura in adults. These products were launched between 2022 and 2025 and generated $638.5 million in sales in 2025.

• Development Programs: This segment encompasses the company’s pipeline of investigational candidates. AXS-05 is being studied for Alzheimer disease agitation and smoking cessation with a supplemental NDA accepted for filing in December 2025 and a PDUFA target action date of April 30 2026. Solriamfetol is in Phase 3 trials for attention deficit hyperactivity disorder major depressive disorder with excessive daytime sleepiness symptoms binge eating disorder and shift work disorder. AXS-12 (reboxetine) is a potent norepinephrine reuptake inhibitor under development for narcolepsy and has received pre NDA meeting support from the FDA. AXS-14 (esreboxetine) is a selective norepinephrine reuptake inhibitor being evaluated for fibromyalgia after an initial NDA refusal to file and a subsequent FORWARD study. AXS-17 (formerly AZD7325) is a GABA A receptor α2 3 positive allosteric modulator acquired for epilepsy treatment. These programs aim to address serious unmet medical needs in neurology and psychiatry.

Axsome holds a differentiated position in the central nervous system therapeutics landscape by leveraging proprietary medicinal chemistry and formulation technologies such as metabolic inhibition and the MoSEIC platform to create products with novel mechanisms of action. The company competes with large pharmaceutical firms including Johnson & Johnson Pfizer GSK AbbVie and specialty biotech firms such as Harmony Biosciences Jazz and Alkermes. Its competitive advantages stem from first in class or best in class profiles, rapid onset of action, and the ability to pursue regulatory efficiencies through the 505 b 2 pathway which can reduce development costs and time to market.

Axsome serves patients suffering from central nervous system disorders such as major depressive disorder excessive daytime sleepiness migraine Alzheimer disease agitation narcolepsy fibromyalgia and epilepsy. Its products are prescribed by physicians and distributed through pharmacies wholesalers and managed care organizations across the United States.

Investment thesis

Bull case

Axsome’s third‑quarter revenue surge of 63% reflects a well‑executed commercial strategy that is beginning to reach maturity across all three product lines. The company’s focus on expanding payer coverage through multiple GPO contracts has lifted AUVELITY’s commercial coverage from 73% to 75% and total coverage to 85% of patient lives, a trajectory that indicates continued upside potential as remaining contract negotiations mature. The simultaneous rise in new prescriber activation—over 5,000 new clinicians for SUNOSI and a 46% increase in AUVELITY prescriptions—suggests that the company’s direct‑to‑consumer campaign and primary‑care outreach are effectively generating organic growth beyond the incremental lift from sales force expansion. These metrics collectively point to a widening addressable market that is unlikely to plateau in the near term, positioning Axsome to capture a larger share of the rapidly growing CNS therapeutic space. {bullet} Management’s emphasis on the high‑margin gross‑to‑net improvement for AUVELITY, moving from the mid‑50s to the high 40s, signals a pricing strategy that is translating into better realized revenue per prescription. The disclosure that the discount improvement is linked to an additional 28 million covered lives indicates that pricing gains are not purely an accounting artifact but are rooted in broader payer acceptance. Given that the company expects this discount range to shift into the low 50s next quarter, the trend suggests a sustainable pricing trajectory that could continue to enhance profitability as market penetration deepens and new GPO contracts expand coverage further. {bullet} Axsome’s pipeline depth, with multiple Phase III studies targeting high‑unmet indications such as binge eating disorder, shift work disorder, and fibromyalgia, offers a diversified growth engine that extends beyond the current product portfolio. The company’s strategic plan to file supplemental NDA for AXS‑05 in Alzheimer’s agitation and NDA for AXS‑12 in narcolepsy within the next 12 months provides a clear, actionable roadmap for product launches that could significantly augment revenue streams. By leveraging existing sales force infrastructure and established payer relationships, Axsome can accelerate commercialization of these new assets without incurring proportionally large incremental costs, creating a potential “pipeline‑to‑pipeline” synergy that can deliver sustained top‑line momentum. {bullet} The recent entry of AUVELITY into the primary‑care segment—now representing about one‑third of prescribers—positions the drug to benefit from the broader prescribing habits of primary‑care physicians who manage depression at the community level. Primary‑care adoption can generate a steady, long‑term prescription pipeline that is less susceptible to specialty‑market fluctuations, thereby adding stability to sales forecasts. Coupled with the company’s aggressive sales‑force expansion and the planned introduction of a dedicated long‑term‑care team for AXS‑05, the commercial network is expanding in multiple directions that align with Axsome’s growth ambitions. {bullet} Axsome’s cash position, at $325 million, provides a comfortable runway to absorb the upfront costs of commercialization while the company moves toward cash‑flow positivity under its current operating plan. Management explicitly stated that the forecasted cash‑flow model already incorporates the projected sales‑force expansion costs associated with future launches, indicating that the company is planning for growth while maintaining a disciplined balance‑sheet approach. This prudent financial management reduces the likelihood of a funding gap that could derail product launches or pipeline investments, thereby mitigating a common risk faced by growth‑stage biotech companies. {bullet} The company’s success in securing a large commercial GPO contract for SYMBRAVO in August demonstrates its ability to negotiate favorable coverage terms even for newer products, an essential factor in a market where GPOs drive significant prescribing volume. By securing such contracts early, Axsome can lock in a sizable patient base before competitors can gain market share, creating a defensible advantage in the headache market that is highly fragmented. The fact that the company already has a second large GPO contract for SYMBRAVO further underscores its commercial traction and provides a platform for rapid scale once the product gains regulatory approval. {bullet} Axsome’s differentiation strategy—offering a first‑in‑class mechanism for Alzheimer’s agitation and a multi‑mechanistic migraine therapy—aligns with a broader industry trend toward precision therapeutics that address specific symptom clusters. The company’s emphasis on synergistic positioning, such as combining SUNOSI with AXS‑12 for narcolepsy patients, illustrates a willingness to explore bundled treatment pathways that could improve patient adherence and create cross‑selling opportunities. Such cross‑product synergies can lead to higher per‑patient revenue and strengthen the company’s competitive moat across its CNS portfolio. {bullet} The company’s continued focus on clinical trials that target high‑unmet needs, coupled with its willingness to pursue regulatory filings in multiple indications, positions it to capitalize on the sizable market opportunities that are often overlooked by investors. While the therapeutic areas are complex, the company’s track record of getting products through the approval pipeline provides a credible probability of success. This, combined with its robust commercial framework, suggests that Axsome is poised to realize significant upside as its pipeline moves into later stages, potentially delivering a strong return on equity over the next five to seven years.

Axsome’s third‑quarter revenue surge of 63% reflects a well‑executed commercial strategy that is beginning to reach maturity across all three product lines. The company’s focus on expanding payer coverage through multiple GPO contracts has lifted AUVELITY’s commercial coverage from 73% to 75% and total coverage to 85% of patient lives, a trajectory that indicates continued upside potential as remaining contract negotiations mature. The simultaneous rise in new prescriber activation—over 5,000 new clinicians for SUNOSI and a 46% increase in AUVELITY prescriptions—suggests that the company’s direct‑to‑consumer campaign and primary‑care outreach are effectively generating organic growth beyond the incremental lift from sales force expansion. These metrics collectively point to a widening addressable market that is unlikely to plateau in the near term, positioning Axsome to capture a larger share of the rapidly growing CNS therapeutic space. {bullet} Management’s emphasis on the high‑margin gross‑to‑net improvement for AUVELITY, moving from the mid‑50s to the high 40s, signals a pricing strategy that is translating into better realized revenue per prescription. The disclosure that the discount improvement is linked to an additional 28 million covered lives indicates that pricing gains are not purely an accounting artifact but are rooted in broader payer acceptance. Given that the company expects this discount range to shift into the low 50s next quarter, the trend suggests a sustainable pricing trajectory that could continue to enhance profitability as market penetration deepens and new GPO contracts expand coverage further. {bullet} Axsome’s pipeline depth, with multiple Phase III studies targeting high‑unmet indications such as binge eating disorder, shift work disorder, and fibromyalgia, offers a diversified growth engine that extends beyond the current product portfolio. The company’s strategic plan to file supplemental NDA for AXS‑05 in Alzheimer’s agitation and NDA for AXS‑12 in narcolepsy within the next 12 months provides a clear, actionable roadmap for product launches that could significantly augment revenue streams. By leveraging existing sales force infrastructure and established payer relationships, Axsome can accelerate commercialization of these new assets without incurring proportionally large incremental costs, creating a potential “pipeline‑to‑pipeline” synergy that can deliver sustained top‑line momentum. {bullet} The recent entry of AUVELITY into the primary‑care segment—now representing about one‑third of prescribers—positions the drug to benefit from the broader prescribing habits of primary‑care physicians who manage depression at the community level. Primary‑care adoption can generate a steady, long‑term prescription pipeline that is less susceptible to specialty‑market fluctuations, thereby adding stability to sales forecasts. Coupled with the company’s aggressive sales‑force expansion and the planned introduction of a dedicated long‑term‑care team for AXS‑05, the commercial network is expanding in multiple directions that align with Axsome’s growth ambitions. {bullet} Axsome’s cash position, at $325 million, provides a comfortable runway to absorb the upfront costs of commercialization while the company moves toward cash‑flow positivity under its current operating plan. Management explicitly stated that the forecasted cash‑flow model already incorporates the projected sales‑force expansion costs associated with future launches, indicating that the company is planning for growth while maintaining a disciplined balance‑sheet approach. This prudent financial management reduces the likelihood of a funding gap that could derail product launches or pipeline investments, thereby mitigating a common risk faced by growth‑stage biotech companies. {bullet} The company’s success in securing a large commercial GPO contract for SYMBRAVO in August demonstrates its ability to negotiate favorable coverage terms even for newer products, an essential factor in a market where GPOs drive significant prescribing volume. By securing such contracts early, Axsome can lock in a sizable patient base before competitors can gain market share, creating a defensible advantage in the headache market that is highly fragmented. The fact that the company already has a second large GPO contract for SYMBRAVO further underscores its commercial traction and provides a platform for rapid scale once the product gains regulatory approval. {bullet} Axsome’s differentiation strategy—offering a first‑in‑class mechanism for Alzheimer’s agitation and a multi‑mechanistic migraine therapy—aligns with a broader industry trend toward precision therapeutics that address specific symptom clusters. The company’s emphasis on synergistic positioning, such as combining SUNOSI with AXS‑12 for narcolepsy patients, illustrates a willingness to explore bundled treatment pathways that could improve patient adherence and create cross‑selling opportunities. Such cross‑product synergies can lead to higher per‑patient revenue and strengthen the company’s competitive moat across its CNS portfolio. {bullet} The company’s continued focus on clinical trials that target high‑unmet needs, coupled with its willingness to pursue regulatory filings in multiple indications, positions it to capitalize on the sizable market opportunities that are often overlooked by investors. While the therapeutic areas are complex, the company’s track record of getting products through the approval pipeline provides a credible probability of success. This, combined with its robust commercial framework, suggests that Axsome is poised to realize significant upside as its pipeline moves into later stages, potentially delivering a strong return on equity over the next five to seven years.

Bear case

The company’s gross‑to‑net discount for all products remains in the high 40% to 70% range, a level that erodes effective margin and may become unsustainable if payer pressure intensifies or if GPO negotiations falter. Management’s expectation that discounts will rise to the low 50% range next quarter implies that the company is already anticipating a continued decline in net pricing, which could offset the revenue growth from expanded coverage and prescriber activation. Investors should be wary that if discounting escalates, profitability will be significantly compressed even as top‑line numbers rise. {bullet} Axsome’s operating leverage is constrained by a rapidly increasing SG&A expense, which grew 57% year‑over‑year to $150 million largely due to commercialization of AUVELITY and launch of SYMBRAVO. While the company projects cash‑flow positivity, the heavy upfront spend on sales force expansion and direct‑to‑consumer marketing represents a cash burn that could outpace revenue growth if product uptake stalls. The dependence on continued expansion of the sales force to sustain growth adds a variable cost layer that may become difficult to manage if the company encounters headwinds in any of its launch markets. {bullet} The company’s most recent product, SYMBRAVO, is still in its first full commercial quarter with a gross‑to‑net discount in the mid‑70% range and a payer coverage of only 52% of patient lives. The launch is highly dependent on the company’s ability to scale prescriber engagement in a fragmented headache market, which has historically seen slow adoption of new therapies. If the company fails to achieve the anticipated prescriber penetration or if GPO contracts do not deliver the expected coverage, SYMBRAVO could experience a slower than projected revenue trajectory, thereby impacting the company’s overall growth narrative. {bullet} Axsome’s pipeline, while deep, is still at a stage where clinical and regulatory uncertainties are significant. The company plans to file supplemental NDA for AXS‑05 in Alzheimer’s agitation and NDA for AXS‑12 in narcolepsy within the next year, but both programs are contingent on positive Phase III data and regulatory approval. If either indication fails to meet clinical endpoints or encounters safety concerns, the projected revenue uplift could be materially reduced, exposing the company to a high risk of delayed or canceled product launches. {bullet} The company’s reliance on GPO contracts for payer coverage introduces a structural risk; the majority of its coverage gains have come from three large GPOs, and the remaining 15–20% of patient lives remain uncovered. If the company is unable to secure additional GPO contracts or if existing contracts are renegotiated at less favorable terms, the company could see a deterioration in coverage that would directly impact prescription volume and revenue growth. Furthermore, the competitive landscape for GPO negotiations is intensifying, with larger pharmaceutical firms lobbying for deeper discounts, potentially squeezing Axsome’s pricing power. {bullet} Axsome’s focus on primary‑care prescribing for AUVELITY, while promising, has not yet proven to be a stable revenue source. Primary‑care prescribers are less familiar with CNS therapies and may rely heavily on specialty referrals, meaning that AUVELITY’s primary‑care penetration could remain limited. The company’s direct‑to‑consumer campaign may help, but the long‑term impact of such advertising on prescription growth is uncertain, and the company has yet to demonstrate a sustained lift in primary‑care prescription rates beyond the initial surge. {bullet} The company’s current net loss of $47 million, driven largely by stock‑based compensation and contingent consideration charges, raises concerns about its ability to sustain operations in the event of a temporary dip in sales or an unexpected regulatory setback. While the company’s cash reserves appear sufficient, any significant slowdown in product adoption or any delay in pipeline approvals could force the company to seek external financing, potentially diluting existing shareholders or compromising strategic flexibility. {bullet} Finally, Axsome’s expansion into multiple indications may strain management’s ability to focus resources on the most promising assets. The company’s announcement of four Phase III trials launching in the same quarter indicates an ambitious timetable that could dilute clinical focus and delay critical data collection. If the company’s clinical development is stretched thin, key trials could miss their endpoints, leading to a cascade of missed regulatory milestones and a potential erosion of investor confidence in the company’s long‑term growth prospects.

The company’s gross‑to‑net discount for all products remains in the high 40% to 70% range, a level that erodes effective margin and may become unsustainable if payer pressure intensifies or if GPO negotiations falter. Management’s expectation that discounts will rise to the low 50% range next quarter implies that the company is already anticipating a continued decline in net pricing, which could offset the revenue growth from expanded coverage and prescriber activation. Investors should be wary that if discounting escalates, profitability will be significantly compressed even as top‑line numbers rise. {bullet} Axsome’s operating leverage is constrained by a rapidly increasing SG&A expense, which grew 57% year‑over‑year to $150 million largely due to commercialization of AUVELITY and launch of SYMBRAVO. While the company projects cash‑flow positivity, the heavy upfront spend on sales force expansion and direct‑to‑consumer marketing represents a cash burn that could outpace revenue growth if product uptake stalls. The dependence on continued expansion of the sales force to sustain growth adds a variable cost layer that may become difficult to manage if the company encounters headwinds in any of its launch markets. {bullet} The company’s most recent product, SYMBRAVO, is still in its first full commercial quarter with a gross‑to‑net discount in the mid‑70% range and a payer coverage of only 52% of patient lives. The launch is highly dependent on the company’s ability to scale prescriber engagement in a fragmented headache market, which has historically seen slow adoption of new therapies. If the company fails to achieve the anticipated prescriber penetration or if GPO contracts do not deliver the expected coverage, SYMBRAVO could experience a slower than projected revenue trajectory, thereby impacting the company’s overall growth narrative. {bullet} Axsome’s pipeline, while deep, is still at a stage where clinical and regulatory uncertainties are significant. The company plans to file supplemental NDA for AXS‑05 in Alzheimer’s agitation and NDA for AXS‑12 in narcolepsy within the next year, but both programs are contingent on positive Phase III data and regulatory approval. If either indication fails to meet clinical endpoints or encounters safety concerns, the projected revenue uplift could be materially reduced, exposing the company to a high risk of delayed or canceled product launches. {bullet} The company’s reliance on GPO contracts for payer coverage introduces a structural risk; the majority of its coverage gains have come from three large GPOs, and the remaining 15–20% of patient lives remain uncovered. If the company is unable to secure additional GPO contracts or if existing contracts are renegotiated at less favorable terms, the company could see a deterioration in coverage that would directly impact prescription volume and revenue growth. Furthermore, the competitive landscape for GPO negotiations is intensifying, with larger pharmaceutical firms lobbying for deeper discounts, potentially squeezing Axsome’s pricing power. {bullet} Axsome’s focus on primary‑care prescribing for AUVELITY, while promising, has not yet proven to be a stable revenue source. Primary‑care prescribers are less familiar with CNS therapies and may rely heavily on specialty referrals, meaning that AUVELITY’s primary‑care penetration could remain limited. The company’s direct‑to‑consumer campaign may help, but the long‑term impact of such advertising on prescription growth is uncertain, and the company has yet to demonstrate a sustained lift in primary‑care prescription rates beyond the initial surge. {bullet} The company’s current net loss of $47 million, driven largely by stock‑based compensation and contingent consideration charges, raises concerns about its ability to sustain operations in the event of a temporary dip in sales or an unexpected regulatory setback. While the company’s cash reserves appear sufficient, any significant slowdown in product adoption or any delay in pipeline approvals could force the company to seek external financing, potentially diluting existing shareholders or compromising strategic flexibility. {bullet} Finally, Axsome’s expansion into multiple indications may strain management’s ability to focus resources on the most promising assets. The company’s announcement of four Phase III trials launching in the same quarter indicates an ambitious timetable that could dilute clinical focus and delay critical data collection. If the company’s clinical development is stretched thin, key trials could miss their endpoints, leading to a cascade of missed regulatory milestones and a potential erosion of investor confidence in the company’s long‑term growth prospects.

Product and Service Breakdown of Revenue (2025)

Breakdown of Revenue (2025)

Peer comparison

Companies in the Biotechnology

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	QNTM	Quantum Biopharma Ltd.	925,748.71 Bn	0.68	-	-
2	LEGN	Legend Biotech Corp	2,886.00 Bn	-4.05	2,805.37	0.32 Bn
3	EVAX	Evaxion A/S	1,751.45 Bn	0.00	47.33	-
4	VRTX	Vertex Pharmaceuticals Inc / Ma	115.93 Bn	29.31	9.66	-
5	REGN	Regeneron Pharmaceuticals, Inc.	74.80 Bn	16.90	5.01	1.99 Bn
6	ALNY	Alnylam Pharmaceuticals, Inc.	38.74 Bn	76.91	9.04	-
7	RVMD	Revolution Medicines, Inc.	28.52 Bn	-25.25	-	-
8	BNTX	BioNTech SE	27.82 Bn	-19.84	15.02	0.41 Bn

Research Tools